

www.glentham.com

According to REACH Regulations (EC) 1907/2006 and (EU) 2020/878

1. Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product code : GT7060

Product name : Hematoxylin Solution, Gill No. 3

CAS number :

Physical form : liquid, mixture

REACH : A registration number is not available for this substance as the substance or its uses

are exempted from registration, the annual tonnage does not require a registration or

the registration is envisaged for a later registration deadline.

1.2 Relevant identified uses of the substance or mixture and uses advised against

PC21: Laboratory chemicals.

1.3 Details of the supplier of the safety data sheet

Company name : Glentham Life Sciences Ltd Telephone : +44 (0) 1225 667 798

Unit 5 Leafield Way Fax : +44 (0) 2033 978 909
Corsham SN13 9SW Email : info@glentham.com
United Kingdom Web : www.glentham.com

1.4 Emergency telephone number

Emergency telephone: NHS Direct 111 (UK, 24 hours), 112 (EU, 24 Hours), +44 (0) 1225 667 798 (09.00 - 17.00 GMT)

number

2. Hazards identification

2.1 Classification of the substance or mixture

Classification under CLP according to (EC) 1272/2008

H302 Acute Tox. 4 H319 Eye Irr. 2A

2.2 Label elements

Label elements under CLP according to (EC) 1272/2008

Pictograms



Signal words Warning

Hazard statements

H302 Harmful if swallowed H319 Causes serious eye irritation

Precautionary statements

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and

easy to do - continue rinsing.

2.3 Other hazards

PBT

This substance is not identified as a PBT substance.

3.0 Composition/information on ingredients

3.2 Mixtures

Page 1 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40



www.glentham.com

Name	Identifier	%	Classification
Ethylene glycol	CAS: 107-21-1 EC: 203-473-3 REACH: Not applicable	25 - 30	H302, Acute Tox. 4 H373, STOT RE 2
Aluminium sulfate	CAS: 16828-11-8 EC: 233-135-0 REACH: Not applicable	8	H318, Eye Dam. 1
Acetic acid	CAS: 64-19-7 EC: 200-580-7 REACH: Not applicable	2.5	H226, Flam. Liq. 3 H314, Skin Corr. 1A
Haematoxylin	CAS: 517-28-2 EC: 208-237-3 REACH: Not applicable	< 1	H302, Acute Tox. 4 H315, Skin Irr. 2 H319, Eye Irr. 2A H335, STOT SE 3 H336, STOT SE 3
Sodium iodate	CAS: 7681-55-2 EC: REACH: Not applicable	<1	H272, Ox. Sol. 2 H302, Acute Tox. 4 H317, Skin Sens. 1 H334, Resp. Sens. 1

4. First aid measures

4.1 Description of first aid measures

Skin contact	Consult a doctor. Drench the affected skin with running water for 10 minutes or longer if substance is still on skin. Remove all contaminated clothes and footwear immediately unless stuck to skin. Transfer to hospital if there are burns or symptoms of poisoning.
Eye contact	Consult a doctor. Transfer to hospital for specialist examination. Bathe the eye with running water for 15 minutes.
Ingestion	Consult a doctor. Do not induce vomiting. Give 1 cup of water to drink every 10 minutes. If unconscious and breathing is OK, place in the recovery position. If unconscious, check for breathing and apply artificial respiration if necessary. Transfer to hospital as soon as possible. Wash out mouth with water.
Inhalation	If breathing becomes bubbly, have the casualty sit and provide oxygen if available. If conscious, ensure the casualty sits or lies down. If unconscious and breathing is OK, place in the recovery position. If unconscious, check for breathing and apply artificial respiration if necessary. Transfer to hospital as soon as possible. Consult a doctor. Remove casualty from exposure ensuring one's own safety whilst doing so.

4.2 Most important symptoms and effects, both acute and delayed

	· · · · · · · · · · · · · · · · · · ·
Skin contact	Blistering may occur. Progressive ulceration will occur if treatment is not immediate. There may be mild irritation at the site of contact.
Eye contact	Corneal burns may occur. May cause permanent damage. There may be irritation and redness.
Ingestion	Blood may be vomited. Corrosive burns may appear around the lips. There may be bleeding from the mouth or nose. There may be irritation of the throat.
Inhalation	Exposure may cause coughing or wheezing. There may be irritation of the throat with a feeling of tightness in the chest. There may be shortness of breath with a burning sensation in the throat.
Delayed / immediate effects	Delayed effects can be expected after long-term exposure. Immediate effects can be expected after short-term exposure. There may be bleeding from the mouth or nose.

4.3 Indication of any immediate medical attention and special treatment needed

Immediate / special treatment

Do not induce vomiting. Eye bathing equipment should be available on the premises.



www.glentham.com

5. Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media for the surrounding fire should be used. Use water spray to cool containers.

5.2 Special hazards arising from the substance or mixture

Exposure hazards

Corrosive. In combustion emits toxic fumes.

5.3 Advice for fire-fighters

Wear protective clothing to prevent contact with skin and eyes. Wear self-contained breathing apparatus.

6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions

Do not attempt to take action without suitable protective clothing - see section 8 of SDS. Do not create dust. Evacuate the area immediately. If outside keep bystanders upwind and away from danger point. Mark out the contaminated area with signs and prevent access to unauthorised personnel. Notify the police and fire brigade immediately. Refer to section 8 of SDS for personal protection details

6.2 Environmental precautions

Alert the neighbourhood to the presence of fumes or gas. Do not discharge into drains or rivers.

6.3 Methods and material for containment and cleaning up

Clean-up procedures

Clean-up should be dealt with only by qualified personnel familiar with the specific substance. Transfer to a closable, labelled salvage container for disposal by an appropriate method.

6.4 Reference to other sections

Refer to section 8 of SDS.

7. Handling and storage

7.1 Precautions for safe handling

Handling requirements

Avoid direct contact with the substance. Avoid the formation or spread of dust in the air. Do not handle in a confined space. Ensure there is sufficient ventilation of the area.

7.2 Conditions for safe storage, including any incompatibilities

Storage conditions

Avoid contact with water or humidity. Keep container tightly closed. Store in cool, well ventilated area.

7.3 Specific end use(s)

No data available.

8. Exposure controls/personal protection

8.1 Control parameters

Workplace exposure limits

Page 3 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40



www.glentham.com

Substance (CAS)	Control Parameter	Value	Notes	Source
Acetic acid (64-19-7)	Long-term Exposure Limit (ppm)	10		UK HSE EH40/2005
	Long-term Exposure Limit (mg m ⁻³)	25		
	Short-term Exposure Limit (ppm)	20	•	
	Short-term Exposure Limit (mg m ⁻³)	50		
	Long-term Exposure Limit (ppm)	25		(EU) 2017/164
	Long-term Exposure Limit (mg m ⁻³)	10	•	
	Short-term Exposure Limit (ppm)	50		
	Short-term Exposure Limit (mg m ⁻³)	20		
Ethane-1,2-diol particulate /apour (107-21-1)	e Long-term Exposure Limit (ppm)	-20	Sk	UK HSE EH40/2005
, apour (101 <u>-</u> 1 1)	Long-term Exposure Limit (mg m ⁻³)	10,52		
	Short-term Exposure Limit (ppm)	-40		
	Short-term Exposure Limit (mg m ⁻³)	-104		
	Long-term Exposure Limit (ppm)	52	Skin	2000/39/EC
	Long-term Exposure Limit (mg m ⁻³)	20	•	
	Short-term Exposure Limit (ppm)	104		
	Short-term Exposure Limit (mg m ⁻³)	40		
Ethylene glycol (107-21-1) Long-term Exposure Limit (ppm)	-20	Sk	UK HSE EH40/2009
	Long-term Exposure Limit (mg m ⁻³)	10,52		
	Short-term Exposure Limit (ppm)	-40		
	Short-term Exposure Limit (mg m ⁻³)	-104		
	Long-term Exposure Limit (ppm)	52	Skin	2000/39/EC
	Long-term Exposure Limit (mg m ⁻³)	20		
	Short-term Exposure Limit (ppm)	104	•	
	Short-term Exposure Limit (mg m ⁻³)	40		
xposure controls				
Engineering measures En	sure there is sufficient ventilation of the area	a.		
	Respiratory protective device with particle filter. Self- contained breathing apparatus must be available in case of emergency.			
Hand protection Pro	otective gloves.			
Eye protection Tig	Tightly fitting safety goggles. Ensure eye bath is to hand. Safety glasses.			

9. Physical and chemical properties

Skin protection

8.2

Protective clothing.



www.glentham.com

9.1 Information on basic physical and chemical properties

Physical state Liquid
Colour Red
Odour No data available.

Melting point/Freezing point

Boiling point/initial boiling point/boiling range
Flammability

No data available.

No data available.

Lower/Upper explosion limit

Flash Point

No data available.

No data available.

No data available.

Auto-ignition temperature
Decomposition temperature
PH
No data available.
Solubility
No data available.

Partition coefficient n-octanol/water
Vapour pressure
Density/relative density
Relative vapour pressure
Particle characteristics
No data available.
No data available.
No data available.

9.2 Other information

No data available.

10. Stability and reactivity

10.1 Reactivity

Stable under recommended transport or storage conditions.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions

Decomposition may occur on exposure to conditions or materials listed below. Hazardous reactions will not occur under normal transport or storage conditions.

10.4 Conditions to avoid

Flames. Hot surfaces. Heat.

10.5 Incompatible materials

Materials to avoid

Strong acids. Strong oxidising agents.

11. Toxicological information

11.1 Information on toxicological effects

a) Acute toxicity

Acetic acid

LD50 Rabbit (Dermal): 1060 mg/kg LD50 Mouse (IV): 525 mg/kg LD50 Rat (Oral): 3.53 g/kg LD50 Mouse (Oral): 4960 mg/kg LD50 Rat (Oral): 4665 mg/kg

Ethane-1,2-diol particulate vapour

LD50 Rat (Oral): 4700 mg/kg LD50 Mouse (Oral): 7500 mg/kg LD50 Guinea pig (Oral): 8200 mg/kg LD50 Dog (Oral): >8810 mg/kg

Ethylene glycol

Page 5 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40



www.glentham.com

LD50 Rat (Oral): 4700 mg/kg LD50 Mouse (Oral): 7500 mg/kg LD50 Guinea pig (Oral): 8200 mg/kg LD50 Dog (Oral): >8810 mg/kg

b) Skin corrosion/irritation

No data available.

c) Serious eye damage/irritation

Serious eye damage/eye irritation (Category 2A)

d) Respiratory or skin sensitisation

No data available.

e) Germ cell mutagenicity

No data available.

f) Carcinogenicity

No data available.

g) Reproductive toxicity

No data available.

h) STOT-single exposure

No data available.

i) STOT-repeated exposure

No data available.

j) Aspiration hazard

No data available.

11.2 Symptoms / routes of exposure

Skin contact	Blistering may occur. Progressive ulceration will occur if treatment is not immediate. There may be mild irritation at the site of contact.
Eye contact	Corneal burns may occur. May cause permanent damage. There may be irritation and redness.
Ingestion	Blood may be vomited. Corrosive burns may appear around the lips. There may be bleeding from the mouth or nose. There may be irritation of the throat.
Inhalation	Exposure may cause coughing or wheezing. There may be irritation of the throat with a feeling of tightness in the chest. There may be shortness of breath with a burning sensation in the throat.
Delayed / immediate effects	Delayed effects can be expected after long-term exposure. Immediate effects can be expected after short-term exposure. There may be bleeding from the mouth or nose.
Other information	No data available.

12. Ecological information

12.1 Toxicity

No data available.

12.2 Persistence and degradability

Biodegradable.

12.3 Bioaccumulative potential

No bioaccumulation potential.

12.4 Mobility in soil

Readily absorbed into soil.

12.5 Results of PBT and vPvB assessment

This substance is not identified as a PBT substance.

12.6 Endocrine disrupting properties

This substance is not identified as having endocrine disrupting properties

12.7 Other adverse effects

Page 6 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40



www.glentham.com

No data available.

13. Disposal considerations

13.1 Waste treatment methods

Disposal operations

Transfer to a suitable container and arrange for collection by specialised disposal company.

NE

The user's attention is drawn to the possible existence of regional or national regulations regarding disposal.

14. Transport information

This product does not require a classification for transport.

15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

This Safety Data Sheet is prepared in accordance with Commission Regulation (EC) 1907/2006, amended by Commission Regulation (EU) 2020/787.

Authorisations/Restrictions

Regulation (EC) 1907/2006, REACH, Annex XIV list of substances subject to vPvB (Article 57e)

authorisation: Toxic for reproduction (Article 57c)

Endocrine disrupting properties (Article 57(f) - environment)

Regulation (EC) 1907/2006, REACH, Annex XVII restrictions on the manufacture, placing No data available.

on the market and use of certain dangerous substances:

Regulation (EC) 1005/2009 on substances that deplete the ozone layer:

No data available.

Regulation (EC) 850/2004 on persistent organic pollutants, amended by (EU) No

No data available.

2019/1021:

15.2 Chemical safety assessment

A chemical safety assessment has not been carried out for the substance or the mixture by the supplier.

16. Other information

H-Statement Full Texts

H226	Flammable liquid and vapour
H272	May intensify fire: oxidizer
H302	Harmful if swallowed
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H373	May cause damage to organs through prolonged or repeated exposure

Abbreviations Full Texts

ADN European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways

ADR European Agreement concerning the International Carriage of Dangerous Goods by Road

ALARP As low as is reasonably practicable CAS Chemical Abstracts Service

CLP Classification, Labelling and Packaging Regulations

COSHH Control of Substances Hazardous to Health

EC Number European Community Number

Page 7 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40





www.glentham.com

EC50 Effective Concentration 50%

EILINCS European List of Notified Chemical Substances

EINECS European Inventory of Existing Commercial Chemical Substances

GHS Globally Harmonised System
HSE Health & Safety Executive UK

IATA International Air Transport Association

IM Intramuscular

IMDG The International Maritime Dangerous Goods Code

IP Intraperitoneal IV Intravascular LD50 Lethal Dose 50%

LOEC Lowest Observable Effective Concentration

LTEL Long Term Exposure Limit

NOEC No Observable Effective Concentration

OECD Organisation for Economic Cooperations and Development

PBT Persistent Bioaccumulative Toxic
PPE Personal Protective Equipment

REACH Registration, Evaluation, Authorisation and Restriction of Chemicals

RID Regulations Concerning the International Carriage of Dangerous Goods by Rail

SC Subcutaneous
SDS Safety Data Sheet
STEL Short Term Exposure Limit
STOT Specific Target Organ Toxicity
VOC Volatile Organic Compounds

vPvB Very Persistent and Very Bioaccumulative

WEL Workplace Exposure Limits

This Safety Data Sheet is prepared in accordance with Commission Regulation (EC) 1907/2006, amended by Commission Regulation (EU) 2020/787.

Disclaimer: Glentham Life Sciences shall not be held liable for any damage resulting from handling or from contact with the above product. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. This document does not guarantee the properties or quality of the product.

Copyright © 2023 Glentham Life Sciences Limited. All rights reserved.

Page 8 of 8 Revision Date: 2023-12-20, Printed: 2023-12-20 12:17:40